Peak Asset Management LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,007 shares of the medical instruments supplier’s stock after selling 627 shares during the period. Becton, Dickinson and comprises approximately 2.5% of Peak Asset Management LLC’s investment portfolio, making the stock its 16th biggest holding. Peak Asset Management LLC’s holdings in Becton, Dickinson and were worth $9,972,000 at the end of the most recent reporting period. Several other institutional investors also recently bought and sold shares of BDX. Solstein Capital LLC bought a new stake in shares of Becton, Dickinson and during the first quarter valued at approximately $28,000. Meridian Wealth Partners LLC bought a new stake in shares of Becton, Dickinson and during the first quarter valued at approximately $28,000. Ameritas Investment Company LLC bought a new stake in shares of Becton, Dickinson and during the first quarter valued at approximately $39,000. Wealthcare Advisory Partners LLC bought a new position in Becton, Dickinson and in the first quarter worth approximately $41,000. Finally, Harbour Investments Inc. bought a new position in Becton, Dickinson and in the first quarter worth approximately $42,000. 84.25% of the stock is owned by hedge funds and other institutional investors. A number of equities analysts recently commented on BDX shares. JPMorgan Chase & Co. downgraded shares of Becton, Dickinson and from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $276.93 to $265.00 in a research note on Friday, August 6th. SVB Leerink reduced their price objective on shares of Becton, Dickinson and from $260.00 to $250.00 and set a “market perform” rating for the company in a research note on Friday, August 6th. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating and set a $262.00 price objective for the company in a research note on Tuesday, August 17th. Finally, Barclays began coverage on shares of Becton, Dickinson and in a report on Monday, May 24th. They issued an “equal weight” rating and a $270.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $272.33. In other Becton, Dickinson and news, Director Rebecca W. Rimel sold 207 shares of the company’s stock in a transaction on Monday, August 30th. The shares were sold at an average price of $252.00, for a total value of $52,164.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink . Also, Director Claire Fraser sold 387 shares of the company’s stock in a transaction on Wednesday, August 18th. The shares were sold at an average price of $251.58, for a total transaction of $97,361.46. The disclosure for this sale can be found here . Insiders have sold 1,370 shares of company stock worth $340,405 over the last three months. Corporate insiders own 0.76% of the company’s stock. NYSE BDX opened at $257.83 on Friday. The firm has a market capitalization of $74.05 billion, a P/E ratio of 40.48, a P/E/G ratio of 2.35 and a beta of 0.76. The company has a current ratio of 1.23, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Becton, Dickinson and Company has a 12-month low of $219.50 and a 12-month high of $267.37. The firm’s fifty day simple moving average is $248.93 and its two-hundred day simple moving average is $246.58. Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Wednesday, August 4th. The medical instruments supplier reported $2.74 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.30. The firm had revenue of $4.89 billion for the quarter, compared to analyst estimates of $4.51 billion. Becton, Dickinson and had a net margin of 9.72% and a return on equity of 16.26%. The business’s quarterly revenue was up 26.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.20 earnings per share. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.9 earnings per share for the current fiscal year. The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 30th. Stockholders of record on Thursday, September 9th will be issued a dividend of $0.83 per share. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend is Wednesday, September 8th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 32.55%. Becton, Dickinson and Profile Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.Featured Story: What is the 52-week high/low?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).